Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294043 · ClinicalTrials.gov registry record · Phase 1
IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
A Phase 1 study of Nontuberculous Mycobacterium Infection, sponsored by Chris Goss.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 10
- Study locations
NCT04294043 is a Phase 1 study of Nontuberculous Mycobacterium Infection that is actively recruiting participants, run by Chris Goss. The registered enrollment target is 40 participants. The trial reports 10 study locations across 10 states.
The verdict
NCT04294043, a Phase 1 study of Nontuberculous Mycobacterium Infection, is actively recruiting participants, sponsored by Chris Goss.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)
Conditions Studied
Interventions
- DRUG Gallium nitrate
Study Locations (10)
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- National Jewish Health - Denver
Maryland
- Johns Hopkins University - Baltimore
Minnesota
- The Minnesota Cystic Fibrosis Center - Minneapolis
Ohio
- Nationwide Children's Hospital - Columbus
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
South Carolina
- Medical University of South Carolina - Charleston
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-06-17 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04294043
The ClinicalTrials.gov registry entry for NCT04294043 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chris Goss, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nontuberculous Mycobacterium Infection appearing as the primary indexed condition, and to 1 intervention - of which Gallium nitrate is the first listed.
NCT04294043 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Alabama, Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT04294043 about?
NCT04294043 is a clinical study titled "IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)". The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)
What is the current status of trial NCT04294043?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-06-17. Estimated completion is 2027-03-31.
What conditions does trial NCT04294043 study?
This clinical trial studies the following conditions: Nontuberculous Mycobacterium Infection.
What interventions are being tested in trial NCT04294043?
The interventions under investigation include: Gallium nitrate (DRUG).
Who is sponsoring clinical trial NCT04294043?
This trial is sponsored by Chris Goss, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04294043 being conducted?
This trial has 10 study locations across Alabama, Colorado, Maryland, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nontuberculous Mycobacterium Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.